Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung

Clinical and Translational Oncology

Volumn 15, Issue 9, 2013, Pages 747-753

  Jeremic B ^a,b   Milicic B ^a   Milisavljevic S ^a  

^a University Hospital   (Serbia)

^b STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

Adenocarcinoma; Chemotherapy; Lung cancer; Radiation therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ETOPOSIDE; PACLITAXEL;

ADULT; ADVANCED CANCER; ARTICLE; BLOOD TOXICITY; BRONCHOPULMONARY TOXICITY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DISTANT METASTASIS FREE SURVIVAL; ESOPHAGUS TOXICITY; FEMALE; GASTRIC TOXICITY; HUMAN; INOPERABLE CANCER; INTERMETHOD COMPARISON; LOW DRUG DOSE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; OSSEOUS TOXICITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SKIN TOXICITY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT FAILURE;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARBOPLATIN; CHEMORADIOTHERAPY; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; PROSPECTIVE STUDIES; RADIOTHERAPY; TIME FACTORS;

EID: 84883288953     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-1000-2     Document Type: Article

References (30)

1. Aupérin A, Le Péchoux C, Rolland E et al (2010) Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol 28:2181-2190
2. Travis WD, Brambilla E, Noguchi M et al (2011) The new IASLC/ATS/ERS International multidisciplinary lung adenocarcinoma classification. J Thorac Oncol 6:244-285
3. Jeremic B, Shibamoto Y, Acimovic L et al (1995) Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 13:452-458
4. Jeremic B, Shibamoto Y, Acimovic L et al (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/ etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 14:1065-1070
5. Jeremic B, Shibamoto Y, Milicic B et al (1998) Concurrent radiochemotherapy for patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. Int J Radiat Oncol Biol Phys 42:1091-1096
6. Jeremic B, Shibamoto Y, Acimovic LJ et al (2001) Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without week-end carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 50:19-25
7. Jeremic B, Milicic B, Acimovic L et al (2005) Concurrent hyperfractionated radiotherapy and low-dose daily carboplatin/paclitaxel in patients with stage III non-small cell lung cancer (NSCLC). Long-term results of a phase II study. J Clin Oncol 23:1144-1151
8. Jeremic B, Milicic B, Milisavljeic S (2012) Concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC). Single institution experience in 600 patients. Int J Radiat Oncol Biol Phys 82:1157-1163
9. Jeremić B, Miličić B, Milisavljevic S (2011) Clinical prognostic factors in patients with locally advanced (stage III) nonsmall cell lung cancer treated with hyperfractionated radiation therapy with and without concurrent chemotherapy: single-Institution Experience in 600 Patients. Cancer 117:2995-3003
10. Jeremic B, Milicic B, Milisavljevic S (2012) Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC). Single institution experience in 600 patients. Clin Transl Oncol 14:613-618
11. Mountain CF (1986) A new international staging system for lung cancer. Chest 89(Suppl 4):225S-233S
12. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for the Treatment and Research of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31:1341-1346
13. Cox JD, Azarnia N, Byhardt RW et al (1991) N2 (clinical) non-small-cell carcinoma of the lung: prospective trials of radiation therapy with total doses 60 Gy by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 20:7-12
14. Liao Z, Komaki R, Stevens C et al (2002) Twice daily irradiation increases locoregional control in patients with medically inoperable or surgically unresectable stage II-IIIB non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 53:558-565
15. Schild SE, Stella PJ, Geyer SM et al (2002) Phase III trial comparing chemotherapy plus once-daily or twice-daily radiotherapy in stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 54:370-378
16. Mauguen A, Le Péchoux C, Saunders MI et al (2012) Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. J Clin Oncol 30:2788-2797
17. Atagi S, Kawahara M Yokoyama A et al. on behalf of the Japan Clinical Oncology Group Lung Cancer Study Group (2012) Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301) Lancet Oncol 13:671-678
18. Ball D, Smith J, Wirth A et al (2002) Failure of T stage to predict survival in patients with non-small-cell lung cancer treated by radiotherapy with or without concomitant chemotherapy. Int J Radiat Oncol Biol Phys 54:1007-1013
19. Socinski MA, Zhang C, Herndon JE et al (2004) Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Ann Oncol 15:1033-1041
20. Buccheri G, Ferrigno D (1994) Prognostic factors in lung cancer: tables and comments. Eur Respir J 7:1350-1364
21. Buccheri G, Ferrigno D (2004) Prognostic factors. Hematol Oncol Clin N Am 18:187-201
22. Ohashi R, Takahashi K, Miura K et al (2006) Prognostic factors in patients with inoperable non-small cell lung cancer - an analysis of long term survival patients. Gan To Kagaku Ryoho 33:1595-1602
23. Machtay M, Seiferheld W, Komaki R et al (1999) Is prolonged survival possible for patients with supraclavicular node metastases in non-small cell lung cancer treated with chemoradiotherapy? Analysis of the Radiation Therapy Oncology Group experience. Int J Radiat Oncol Biol Phys 44:847-853
24. Komaki R, Scott CB, Byhardt RW et al (1998) Failur pattern by prognostic group determined by recursive partitioning analysis (RPA) of 1547 patients on four Radiation Therapy Oncolgoy Group (RTOG) studies in inoperable nonsmall-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 42:263-267
25. Yeo S-G, Cho M-J, Kim S-Y et al (2005) Treatment outcomes of three-dimensional conformal radiotherapy for stage III non-small cell lung cancer. Cancer Treat Res 37:273-278
26. Russell A, Pajak T, Selim H et al (1991) Prophylactic cranial irradiation for lung cancer patients at high risk for development of cerebral metastasis: results of a prospective randomized trial conducted by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 21:637-643
27. Werner-Wasik M, Scott C, Cox JD et al (2000) Recursive partitioning analysis of 1999 Radiation Therapy Oncology Group (RTOG) patients with locally-advanced non-small-cell lung cancer (LA-NSCLC): identification of five groups with different survival. Int J Radiat Oncol Biol Phys 48:1475-1482
28. Sause WT, Scott C, Taylor S et al (1995) Radiation Therapy Oncolgoy Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198-205
29. Cox JD, Scott CB, Byhardt RW et al (1999) Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 43:505-509
30. Stuschke M, Eberhardt W, Pottgen C et al (1999) Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 17:2700-2709